NEW YORK (
) -- The following stocks hit 52-week highs on Tuesday:
"We are raising our 12m PO to $110 from $106, based on an 18.5x forward P/E on our 2013 EPS estimates, following meetings with mgmt last week and incrementalanalysis of the competitive setting," Bank of America Merrill Lynch analysts wrote in a May 11 report. "CL is our top large cap pick. We believe 6%+ organic sales is sustainable in the medium-term, and EBIT growth and earnings quality are both likely to improve thru 2012, which should set CL apart from most of its Staples peers, offering potential for even higher relative valuation."
Shares of Colgate-Palmolive hit a 52-week high on Tuesday of $101.60. The stock's 52-week low of $78.62 was set on Aug. 9.
Colgate-Palmolive trades at an estimated price-to-earnings ratio for next year of 17.12 times; the average for personal products companies is 15.4. For comparison,
has a lower forward P/E of 15.42.
Fifteen of the 25 analysts who cover Colgate-Palmolive rated it hold. Eight analysts gave the stock a buy rating and two rated it sell.
The stock has risen 9.99% year to date.
"ALGT reported 1Q EPS of $1.12 vs. our and consensus estimate of $1.01," Sterne Agee analysts wrote in a May 1 report. "1Q was a strong operating beat, with operating income of $36M coming in $2M better ($0.06 per share) than our estimate. Revenue was $1.6M below forecast, due largely to scheduled PRASM 80 bps below forecast. Lower fuel and labor unit labor cost more than offset the revenue shortfall. In particular, fuel efficiency was 4.5% better than forecast, accounting for the better fuel expense, driven by the effect of an increased number of more fuel efficient Boeing 757s in operation."
Shares of Allegiant Travel hit a 52-week high on Tuesday of $64.70. The stock's 52-week low of $40.31 was set on Aug. 3.
Allegiant's forward P/E is 13.36; the average for airlines is 6.8. For comparison,
Delta Air Lines
has a lower forward P/E of 4.36.
Eleven of the 18 analysts who cover Allegiant rated it buy. Six analysts gave the stock a hold rating and one rated it sell.
The stock has gained 21.92% year to date.
"With a maturing ANDA pipeline, new opportunities in injectable drug shortages, recent expansion into the OTC ophthalmic segment, in tandem with additional opportunities to enhance its product portfolio through acquisitions, we continue to believe that Akorn is well positioned for 25% annual EPS growth over the next three years," Deutsche Bank analysts wrote in a May 9 report.
Shares of Akorn hit a 52-week high Tuesday of $13.25. The stock's 52-week low of $6.18 was set on June 17.
Akorn's forward P/E is 18.33; the average for pharmaceutical companies is 35.77. For comparison,
has a lower forward P/E of 12.17.
Five of the six analysts who cover Akorn rated it buy; one analyst gave the stock a sell rating.
The stock has risen 17.27% year to date.
-- Written by Alexandra Zendrian
>To contact the writer of this article, click here:
>To submit a news tip, send an email to:
>To follow the writer on Twitter, go to